Pfizer: A Pharmaceutist’s Fable

The past twelve months have seen the stock drift, a listless vessel upon a turbulent sea of bullish enthusiasm elsewhere. A mere 2% decline, you say? A trifle, perhaps, until one considers the roaring tide lifting all other boats. It suggests a hesitancy, a suspicion that something is… amiss. Investors, those notoriously fickle creatures, seem to be holding their breath, awaiting a sign, a tremor, anything to break the spell.







